NO20060678L - Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer - Google Patents

Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer

Info

Publication number: NO20060678L
Authority: NO; Norway
Prior art keywords: optionally substituted; alkyl; alkyloxy; polyhaloci; polyhaloc
Prior art date: 2003-07-16

Application number

NO20060678A

Other languages

English (en)

Norwegian (no)

Inventor

Ludwig Paul Cooymans

Eddy Jean Edgard Freyne

Werner Constant Joha Embrechts

Christopher John Love

Marc Willems

Nele Vandermaesen

Peter Jacobus Johan Buijnsters

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-16

Filing date

2006-02-10

Publication date

2006-02-10

2006-02-10 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2006-02-10 Publication of NO20060678L publication Critical patent/NO20060678L/no

Links

239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 title 1
YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 title 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 6
125000000217 alkyl group Chemical group 0.000 abstract 4
125000003545 alkoxy group Chemical group 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
150000001204 N-oxides Chemical class 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
150000001412 amines Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000003373 pyrazinyl group Chemical group 0.000 abstract 1
125000002098 pyridazinyl group Chemical group 0.000 abstract 1
125000004076 pyridyl group Chemical group 0.000 abstract 1
125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20060678A 2003-07-16 2006-02-10 Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer NO20060678L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP0350310		2003-07-16
PCT/EP2004/051455 WO2005012307A1 (en)	2003-07-16	2004-07-12	Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors

Publications (1)

Publication Number	Publication Date
NO20060678L true NO20060678L (no)	2006-02-10

Family

ID=34112425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060678A NO20060678L (no)	2003-07-16	2006-02-10	Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer

Country Status (26)

Country	Link
US (2)	US7560458B2 (pt)
EP (1)	EP1658292B1 (pt)
JP (1)	JP2009514782A (pt)
KR (1)	KR20060120393A (pt)
CN (1)	CN100404536C (pt)
AP (1)	AP2006003486A0 (pt)
AR (1)	AR045698A1 (pt)
AT (1)	ATE370142T1 (pt)
AU (1)	AU2004260738B2 (pt)
BR (1)	BRPI0412596A (pt)
CA (1)	CA2531333A1 (pt)
DE (1)	DE602004008303T2 (pt)
DK (1)	DK1658292T3 (pt)
EA (1)	EA010109B1 (pt)
ES (1)	ES2290754T3 (pt)
IL (1)	IL173139A (pt)
JO (1)	JO2460B1 (pt)
MX (1)	MXPA06000540A (pt)
NO (1)	NO20060678L (pt)
NZ (1)	NZ545058A (pt)
PA (1)	PA8607001A1 (pt)
PL (1)	PL1658292T3 (pt)
PT (1)	PT1658292E (pt)
TW (1)	TW200524935A (pt)
WO (1)	WO2005012307A1 (pt)
ZA (1)	ZA200600385B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da)	2002-07-29	2010-04-26	Rigel Pharmaceuticals Inc	Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
DK1658292T3 (da) *	2003-07-16	2007-11-12	Janssen Pharmaceutica Nv	Triazologyrimidinderivater som glycogensynthasekinase 3 - inhibitorer
BRPI0413018B8 (pt)	2003-07-30	2021-05-25	Rigel Pharmaceuticals Inc	composto, e, uso de um composto
BRPI0413616B8 (pt) *	2003-08-15	2021-05-25	Irm Llc	2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
EP2145888A1 (en) *	2003-09-18	2010-01-20	Conforma Therapeutics Corporation	Deazapurine derivatives as HSP90-Inhibitors
EP1807085B1 (en)	2004-09-20	2013-08-21	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084212A (zh)	2004-09-20	2007-12-05	泽农医药公司	杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
JP5149009B2 (ja)	2004-09-20	2013-02-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
AU2005286793A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
WO2006034279A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as therapeutic agents
CN101084207A (zh)	2004-09-20	2007-12-05	泽农医药公司	杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
CA2580857A1 (en)	2004-09-20	2006-09-28	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
AU2005298637B8 (en)	2004-10-29	2012-12-06	Janssen Sciences Ireland Uc	HIV inhibiting bicyclic pyrimidine derivatives
WO2006076442A2 (en) *	2005-01-14	2006-07-20	Janssen Pharmaceutica N.V.	Triazolopyrimidine derivatives
AU2006343359A1 (en)	2005-06-03	2007-11-15	Xenon Pharmaceuticals Inc.	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US7491732B2 (en) *	2005-06-08	2009-02-17	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
US8119655B2 (en) *	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
EP2377530A3 (en)	2005-10-21	2012-06-20	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en)	2005-10-31	2008-07-16	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US8962643B2 (en)	2006-02-24	2015-02-24	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
SG175609A1 (en)	2006-10-09	2011-11-28	Takeda Pharmaceutical	Kinase inhibitors
US7968536B2 (en) *	2007-06-29	2011-06-28	Millennium Pharmaceuticals, Inc.	Heterocyclic compounds useful as RAF kinase inhibitors
AR067354A1 (es)	2007-06-29	2009-10-07	Sunesis Pharmaceuticals Inc	Compuestos utiles como inhibidores de la raf quinasa
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CA2798578C (en)	2010-05-21	2015-12-29	Chemilia Ab	Novel pyrimidine derivatives
AU2012230229A1 (en)	2011-03-24	2013-10-10	Noviga Research Ab	Novel pyrimidine derivatives
AU2012367141B2 (en) *	2012-01-28	2016-12-22	Merck Patent Gmbh	Triazolo[4,5-d]pyrimidine derivatives
JP6049768B2 (ja)	2012-03-07	2016-12-21	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	トリアゾロピラジン誘導体
AU2014224975B2 (en) *	2013-03-05	2017-09-14	Merck Patent Gmbh	Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
EP2964648B1 (en)	2013-03-05	2016-11-16	Merck Patent GmbH	9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
ES2637721T3 (es)	2013-05-06	2017-10-16	Merck Patent Gmbh	Macrociclos como inhibidores de quinasa
EP3226861A2 (en) *	2014-12-05	2017-10-11	Centre National de la Recherche Scientifique (CNRS)	Compounds for treating cystic fibrosis
US11370793B2 (en)	2015-08-27	2022-06-28	Nantneuro, Llc	Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
US11203576B2 (en)	2016-03-11	2021-12-21	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
AU2020218366A1 (en)	2019-02-08	2021-09-16	Frequency Therapeutics, Inc.	Valproic acid compounds and Wnt agonists for treating ear disorders
WO2025104079A1 (en) *	2023-11-17	2025-05-22	Helmholtz-Zentrum für Infektionsforschung GmbH	Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5962594A (ja) *	1982-09-30	1984-04-10	Ss Pharmaceut Co Ltd	３，５―ジ置換―トリアゾロピリミジン誘導体
US20020040031A1 (en) *	2000-07-07	2002-04-04	Glasky Michelle S.	Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US6737085B2 (en) *	2000-11-01	2004-05-18	Tokiwa Phytochemical Co., Ltd.	Apocynum venetum extract for use as antidepressant
EP1347972A1 (en) *	2000-12-19	2003-10-01	Smithkline Beecham Plc	Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors
DK1658292T3 (da) *	2003-07-16	2007-11-12	Janssen Pharmaceutica Nv	Triazologyrimidinderivater som glycogensynthasekinase 3 - inhibitorer

2004
- 2004-07-12 DK DK04766189T patent/DK1658292T3/da active
- 2004-07-12 PL PL04766189T patent/PL1658292T3/pl unknown
- 2004-07-12 CA CA002531333A patent/CA2531333A1/en not_active Abandoned
- 2004-07-12 CN CNB2004800201486A patent/CN100404536C/zh not_active Expired - Fee Related
- 2004-07-12 ES ES04766189T patent/ES2290754T3/es not_active Expired - Lifetime
- 2004-07-12 AP AP2006003486A patent/AP2006003486A0/xx unknown
- 2004-07-12 NZ NZ545058A patent/NZ545058A/en not_active IP Right Cessation
- 2004-07-12 MX MXPA06000540A patent/MXPA06000540A/es active IP Right Grant
- 2004-07-12 JO JO200496A patent/JO2460B1/en active
- 2004-07-12 EA EA200600258A patent/EA010109B1/ru not_active IP Right Cessation
- 2004-07-12 WO PCT/EP2004/051455 patent/WO2005012307A1/en not_active Ceased
- 2004-07-12 JP JP2006519926A patent/JP2009514782A/ja not_active Withdrawn
- 2004-07-12 KR KR1020057024541A patent/KR20060120393A/ko not_active Ceased
- 2004-07-12 EP EP04766189A patent/EP1658292B1/en not_active Expired - Lifetime
- 2004-07-12 BR BRPI0412596-7A patent/BRPI0412596A/pt not_active IP Right Cessation
- 2004-07-12 PT PT04766189T patent/PT1658292E/pt unknown
- 2004-07-12 DE DE602004008303T patent/DE602004008303T2/de not_active Expired - Lifetime
- 2004-07-12 AT AT04766189T patent/ATE370142T1/de active
- 2004-07-12 US US10/564,844 patent/US7560458B2/en not_active Expired - Fee Related
- 2004-07-12 AU AU2004260738A patent/AU2004260738B2/en not_active Ceased
- 2004-07-15 TW TW093121066A patent/TW200524935A/zh unknown
- 2004-07-15 PA PA20048607001A patent/PA8607001A1/es unknown
- 2004-07-15 AR ARP040102496A patent/AR045698A1/es not_active Application Discontinuation
2006
- 2006-01-12 IL IL173139A patent/IL173139A/en not_active IP Right Cessation
- 2006-01-13 ZA ZA200600385A patent/ZA200600385B/en unknown
- 2006-02-10 NO NO20060678A patent/NO20060678L/no not_active Application Discontinuation
2008
- 2008-09-16 US US12/211,361 patent/US20090036471A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20060205721A1 (en)	2006-09-14
ZA200600385B (en)	2007-05-30
BRPI0412596A (pt)	2006-09-19
MXPA06000540A (es)	2006-03-30
EA010109B1 (ru)	2008-06-30
TW200524935A (en)	2005-08-01
CA2531333A1 (en)	2005-02-10
PA8607001A1 (es)	2005-05-10
AU2004260738A1 (en)	2005-02-10
EA200600258A1 (ru)	2006-06-30
AP2006003486A0 (en)	2006-02-28
DE602004008303T2 (de)	2008-05-08
DK1658292T3 (da)	2007-11-12
US20090036471A1 (en)	2009-02-05
US7560458B2 (en)	2009-07-14
PT1658292E (pt)	2007-10-25
NZ545058A (en)	2008-05-30
EP1658292A1 (en)	2006-05-24
KR20060120393A (ko)	2006-11-27
DE602004008303D1 (de)	2007-09-27
AR045698A1 (es)	2005-11-09
ES2290754T3 (es)	2008-02-16
WO2005012307A1 (en)	2005-02-10
CN1823068A (zh)	2006-08-23
IL173139A (en)	2010-04-29
AU2004260738B2 (en)	2009-07-16
JP2009514782A (ja)	2009-04-09
EP1658292B1 (en)	2007-08-15
IL173139A0 (en)	2006-06-11
ATE370142T1 (de)	2007-09-15
JO2460B1 (en)	2009-01-20
CN100404536C (zh)	2008-07-23
PL1658292T3 (pl)	2008-01-31

Legal Events

Date	Code	Title	Description
2011-02-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20060678L (no)	2006-02-10	Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer
WO2005012304A3 (en)	2007-04-26	Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
PE20161066A1 (es)	2016-10-30	Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CO6241157A2 (es)	2011-01-20	"derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
CY1112642T1 (el)	2016-02-10	Παραγωγα 4-(πυριδιν-4-υλο)-1η-[1,3,5]τριαζιν-2-ονης ως αναστολεις της gsκ3-βετα για τη θεραπεια των νευροεκφυλιστικων ασθενειων
NO20041891L (no)	2004-05-07	Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer
NO20041911L (no)	2004-05-10	Heteroarylaminer som glykogensyntase-kinase 3beta-inhibitorer (GSK3-inhibitorer)
AR030553A1 (es)	2003-08-27	Uso de derivados de tiazolilo 2,4-disustituidos para la fabricacion de un medicamento para la prevencion o el tratamiento de enfermedades mediadas a traves de citoquinas, derivados de tiazolilo 2,4-disustituidos, composiciones farmaceuticas que los comprenden, procesos para preparar dichos derivados
PE20191613A1 (es)	2019-11-05	Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
AR067327A1 (es)	2009-10-07	Derivados de piperidina / piperazina
NO2012010I2 (no)	2013-09-02	Rilpivirin samt farmasøytisk akseptable addisjonssalter derav innbefattende hydrokloridsaltet av Rilpivirin
WO2008007123A3 (en)	2008-02-28	Pharmaceutical compounds
NO20073960L (no)	2007-09-24	Pyrazolderivater for inhibering av CDK og GSK
NO20073926L (no)	2007-10-01	Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
MX2012001661A (es)	2012-03-16	Mezclas de pesticidas mesoionicos.
ATE390421T1 (de)	2008-04-15	Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
RU2009148320A (ru)	2011-07-20	Производные пиперидина/пиперазина
BR0211887A (pt)	2004-09-21	Derivados de triazolil 2-amino-4,5-trissubstituìdo
CO2020012353A2 (es)	2021-01-18	Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos
AR066154A1 (es)	2009-07-29	Derivados de piperidina / piperazina
DE602007004740D1 (de)	2010-03-25	Antibiotische spiroderivate
EP1867331A4 (en)	2009-04-08	TRIAZOLE DERIVATIVE AND USE THEREOF
AR070073A1 (es)	2010-03-10	Derivados de imidazo[1, 2 - a]piridin-2-carboxamidas, intermediarios para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades que implican a los receptores not.
PE20252682A1 (es)	2025-11-24	Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlrp3 para el tratamiento de, por ejemplo, enfermedades inflamatorias
WO2006075023A3 (en)	2006-09-28	Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors